juststock
NKGen Biotech (NASDAQ:NKGN) said it has dosed its first patient in a Phase 1/2a study of its cell therapy SNK01 in the treatment of moderate Alzheimer’s disease, AD.
The biotech company said the Phase 1 portion of the study will help determine the maximum tolerated and/or recommended dose for the Phase 2 portion, which will be a randomized double-blind trial evaluating the safety and efficacy of the treatment in AD.
NKGen said the first patient received a dose of 6 billion cells, 50% more than the maximum dose in a prior Phase 1 study. The company said it hopes the increased dose will show “even greater cognitive benefit and greater effects in protein and neuroinflammation levels.
The company plans to conduct an interim data readout from the study in Q3 2024.
NKGen went public through a SPAC merger with Graf Acquisition Corp. IV earlier this year.
